Nutranomics (NNRX) Glucozyme(TM) Human Clinical Study Results Nearing a Public Release Date

http://pennyomega.com/img/penny_omega_logo.jpg

chartstockalert

http://pennyomega.com/img/nnrx.jpg Nutranomics, Inc. (OTCBB:NNRX) (OTCQB:NNRX)

NNRX reported that the results of human patient clinical studies undertaken by the Company regarding Glucozyme(TM) are nearing a public release date.

Glucozyme is a proprietary nutritional supplement being developed by NNRX that has been shown to aid in the processing of sugars to maintain proper glucose and insulin levels in patients with diabetes and pre-diabetes.

Following the conclusion of the latest Glucozyme clinical studies conducted in Japan and Mexico, the resulting new patient data was compiled and compared with previous testing conducted in North America prior to submission for product approval and distribution in several world markets.

Prediabetes is a condition where blood glucose levels are higher than normal but not high enough to be called diabetes. Studies have shown that by losing weight and increasing physical activity people can prevent or delay prediabetes from progressing to diabetes.

Diabetes is a group of diseases marked by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Diabetes can lead to serious complications and premature death, but people with diabetes can take steps to control the disease and lower the risk of complications.

Facts About Diabetes: A Leading Cause of Death in the U.S (National Diabetes Education Program)

- Diabetes is the seventh leading cause of death listed on U.S. death certificates.

- Cardiovascular disease is the leading cause of death among people with diabetes — about 68 percent die of heart disease or stroke.

- The overall risk for death among people with diabetes is about double that of people without diabetes.

According to NNRX, following the successful release of results from the clinical studies, Glucozyme will be one step closer to helping patients manage their glucose levels more effectively and potentially prevent diabetes from impacting their lives dramatically

NNRX anticipates that data compilation and analysis from the Glucozyme clinical studies will be made available within the next 2-3 weeks at which time NNRX expects to release an additional statement.

http://pennyomega.com/img/nnrx_chart.jpg

NNRX is engaged in research and development of nutritional food products. In 1997, NNRX produced and branded its own product line, and began to sell to the retail outlets and to the public. NNRX has also produced formulas for hundreds of other companies. NNRX has sales representatives throughout North America and Asia.

More about Nutranomics, Inc. (OTCBB:NNRX) (OTCQB:NNRX) at www.nutranomics.com

********************************

Read Full Disclaimer at http://pennyomega.com/disclaimer